期刊
MOLECULAR PSYCHIATRY
卷 24, 期 8, 页码 1112-1134出版社
SPRINGERNATURE
DOI: 10.1038/s41380-018-0342-8
关键词
-
资金
- Swedish Foundation for Strategic Research (SSF)
- Swedish Research Council [05817, 02695, 06086]
- Regional Agreement on Medical Training and Clinical Research (ALF) for Stockholm County Council
- Foundation for Old Servants
- Axel Linder's Foundation
- Gun and Bertil Stohne's Foundation
- KI Foundations
- Swedish Brain Foundation
- Swedish Alzheimer's Foundation
- Swedish Dementia Association
- Ake Wiberg Foundation
- EU FW7 large-scale integrating project INMiND
The accumulation of pathological misfolded tau is a feature common to a collective of neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is the most common. Related tauopathies include progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), Down's syndrome (DS), Parkinson's disease (PD), and dementia with Lewy bodies (DLB). Investigation of the role of tau pathology in the onset and progression of these disorders is now possible due the recent advent of tau-specific ligands for use with positron emission tomography (PET), including first-(e.g., [F-18] THK5317, [F-18] THK5351, [F-18] AV1451, and [C-11] PBB3) and second-generation compounds [namely [F-18] MK-6240, [F-18] RO-948 (previously referred to as [F-18] RO69558948), [F-18] PI-2620, [F-18] GTP1, [F-18] PM-PBB3, and [F-18] JNJ64349311 ([F-18] JNJ311) and its derivative [F-18] JNJ-067)]. In this review we describe and discuss findings from in vitro and in vivo studies using both initial and new tau ligands, including their relation to biomarkers for amyloid-beta and neurodegeneration, and cognitive findings. Lastly, methodological considerations for the quantification of in vivo ligand binding are addressed, along with potential future applications of tau PET, including therapeutic trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据